SMARCB1 and AL amyloidosis: We found that treatment of the SMARCB1 deficient cell lines with either bortezomib or MLN2238 led to inhibition of the proteasome to a similar extent observed when the multiple myeloma cell line RPMI8226 was treated (Figure 5—figure supplement 1b; Materials and methods).